Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
Last point, a vaccine, regardless of whether it has 50m doses or 1b doses still relies on the total acceptable adoption by the public and country infrastructure to administer the treatment. That’s pretty much a constant and will take a significant period to vaccinate 70% of the global population to help irradiate the disease.
Imo, following the AstraZeneca news, we are at a point were the risk surrounding vaccination news is squed to the upside for testing stocks rather than downside imo. If we are not already their.
Approx 70m shares have been traded in the last 6 working days. With the total share register at 252m the rebalancing will continue today until Imo the buyers outweigh the sellers and the share price moves back up.
Newflow between now and year end should be pretty consistent and we are at the business end of a period of significant news.
I personally can’t wait.
As a relatively new investor my patience isn’t wearing thin, the shareholder register is currently rebalancing with the average purchase price reducing in accordance with the current consolidation and high volume.
We have known about vaccines for months now, but with the shareholder register consisting mainly of private investors, the drop on V news was bound to see some bed wetters fall out.
So with most of the remaining jittery investors leaving yesterday and those investors who were waiting on the sidelines worried about the next vaccine news seeing little impact on the share price, imo it’s game on.
Share price had a higher low yesterday than last Monday and 100p was good support. In addition to some good buying into close yesterday, even an 8p move to 115p would bring additional momentum as people hate to miss a good opportunity, regardless of if they have currently sold or reduced their current position.
I understand the longer term shareholders frustration as news according to the company is imminent, but equally in third party hands. I don’t believe that anyone more than the company want to deliver on what they have promised.
Just look how easy sentiment shifts, the same applies to both directions.
https://medusa19.com/?utm_source=googleads&utm_campaign=%7Bcampaign%7D&utm_content=%2Bmedusa%20%2B19&gclid=Cj0KCQiAwMP9BRCzARIsAPWTJ_Fa7c2qb7pjI0J6rX0yx9FGNIMvWPZHT62xCSZUDB4yRCM9EY6AxIwaAg4QEALw_wcB
Such an interesting website, really puts the project into perspective.
Patience, this is one hell of accomplishment, product.
To many constructive pieces of the puzzle through multiple government sources for the larger plan to not unfold with AVACTA also keen but unable to reveal the commercial details until completion of the trials. This is now imminent.
https://amp-theguardian-com.cdn.ampproject.org/c/s/amp.theguardian.com/world/2020/jun/22/coronavirus-spit-test-to-be-trialled-in-southampton
With the BAMS test potentially at the forefront of some of these plans.
https://isohelix.com/products/genefix-saliva-dna-collection-device/
I could be wrong here, but I thought that mologic were a non profit organization with an emphasis on Africa?
Yes Odx will benefit from manufacturing these tests with a margin. But the tests are to go to third world countries?
Spoke to a chemist who works in tech transfer for mass production and would go through a similar process to that of Avacta. He said many aspects of the verification and evaluation would be happening in conjunction with the production of the master batch. Many turning cogs that would need to be compressed within a short time frame. A carefully constructed plan is essential to the future rollout, with the more prudent approach likely resulting in a successful rollout without hiccups.
Also said that testing will continue long after vaccinations, for sports venues (stadiums), hospitality (certain venues), flying, cruises. If anything to reassure consumers that it’s safe to return.
I know I would personally feel safer to return to a football stadium where we contribute to the atmosphere through our chanting if they had introduced football passports with unique codes ensuring the test was taken a number of hours before entry to the stadium. Even if that meant I had to pay more for the privilege.
What we do know is that between now and year end, that over the course of the next 6 weeks, we can expect a significant period of newsflow from Avacta which will get rid of the bed wetters.
We are at a sensible market cap for where the company is, as some have pointed out, high risk, high return.
When we were at £2.10 expecting good news the expectation was for the company to go onto £4/10. Those targets haven’t changed in the event the company delivers. That’s a lot of blue sky from here.
It’s also true to say that Avacta twitter activity is strongly correlated to upcoming newsflow. I am very confident for this coming week.
Due to loss of patience will have a greater impact on the next RNS concerning commercial Covid testing progress. I am reading a lot, and I’m constantly trying to evaluate shareholder sentiment. The more investors that lose patience and exit the more powerful the next move up will be.
Keep it up, I’m enjoying it
Quidel Corp has a high correlation due to its relative low market cap to the likes of other players such as Abbott.
If the rebound in America and the continued reports on mass testing is anything to go by, today will be a powerful day for a rebound imo.
‘We will sell everything we produce’, patience is the key to stock market reruns.
They will simply use this as an opportunity to flash the stock down while know-one will be able to take advantage of the lower prices.
The market will forward price this known information given the markets previous experience with the significant drop.
I don’t plan to be fooled. If we get the update we are all waiting for before this next vaccine then everyone will be complaining about how corrupt the market makers were for hitting all the stops. Yet knowone could buy in any real quantity.
Imo
I honestly don’t think the market truly grasps the shear scale of demand for tests v supply. We have already been told that the government is aiming for sovereign supply.
One thing we know is this test is coming. For Abbington to contractually agree to reserve a proportion of its capacity towards a test, they need to have every confidence that the test they are going to make will come to fruition and deliver total demand if required. That’s some commitment on Abbingtons behalf.
Completion of the batches which would of been internally validated before the approval process takes place will light a match under this company, we simply have too many pieces of the puzzle for it not to all fit.
Essentially the UK will take anything the sovereign suppliers can produce. Prove the concept of mass testing in the UK and the demand from abroad will be mind blowing.
Tests will work in conjunction with the vaccines, as new vaccines come on stream, the capacity of those being able to administer remains a relative constant. Throwing money at the virus and we will beat it.
But the path of global immunity will take time to reach the 60/70% global population threshold.
Someone was buying aggressively this morning too. That UT was on top of the late flurry of trades when the book flipped. Was a relatively strong finish, with NT also dampening down the rise.
I think we are as good as imminent, as imminent could be. More importantly we closed above the 200 moving average.
https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/lateral-flow-devices-results
Test 2 - rapid Sylvia test now also part of the equation?
If so wow, this really is under the radar. All taken form company website:
https://bha-medical.com/bha-medical-catenae-joint-venture/?v=fb1c5b0d2f97
And updated as of the 23rd October.
Will be checking into to ASX at 22:30 tonight to read the RNS, very exciting.
It’s pretty clear that the government will also take all that we can produce. It was suggested that the world requires billions of tests and the global production capacity is falling short in a big way.
Cases have spiked in a local school near to me and is now the leading hotspot for cases in our county. Currently tier 1, it’s only a matter of time before they introduce tier 4 and then only way out of this mess is testing.
This isn’t just the mologic antigen test, it will be an upcoming deal with AVCT:
‘ Due to the potential significant interest in an antigen rapid test, we are currently investigating further capacity expansion of the Alva site.’
Odx
A defensive play against the backdrop of a falling Covid related global market with significant near term catalysts.
Just the whisper of a Sylvia test made this hit 210p the other day. Imagine what an RNS confirming completion of the master batch and a lead time to approval would do.
Patience.
Do we have a link to group please?
The underlying book is getting stronger while L2 is attempting to represent a different story at 31 v 33.5p.
I think we could see a late move up. I have purchased another 32k. Will be buying more next week if it falls back.